Think Outside the Box With Intravenous Iron—The New Ferric Carboxymaltose FDA Boxed Warning
This Viewpoint discusses the new US Food and Drug Administration (FDA) boxed warning for intravenous ferric carboxymaltose, how the warning does not go far enough in explaining the potential dangers, and the risks vs benefits of the drug’s use.
Authors
- Michael Auerbach (ORCID: https://orcid.org/0000-0003-0707-8647)
- Hanny T. Al-Samkari (ORCID: https://orcid.org/0000-0001-6175-1383)
- Scott E. Olitsky
Institutions
- Harvard University (US)
- Georgetown University (US)
- Massachusetts General Hospital (US)
- Cure HHT (US)
- Mass General Brigham (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-11-09
- DOI
- https://doi.org/10.1001/jama.2026.21147
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00